Methyl substitution on the piperidine ring of N-[ω-(6- methoxynaphthalen-1-yl)alkyl] derivatives as a probe for selective binding and activity at the σ1 receptor

Journal of Medicinal Chemistry

Volumn 48, Issue 26, 2005, Pages 8237-8244

  Berardi, Francesco ^a   Ferorelli, Savina ^a   Abate, Carmen ^a   Pedone, Maria P ^a   Colabufo, Nicola A ^a   Contino, Marialessandra ^a   Perrone, Roberto ^a  

^a UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (6 METHOXYNAPHTHALEN 1 YL)BUTYL]PIPERIDINE; 3,3 DIMETHYL 1 [3 (6 METHOXYNAPHTHALEN 1 YL)PROPYL]PIPERIDINE; DELTA8 DELTA7 STEROL ISOMERASE; ISOMERASE; METHYL GROUP; N (6 METHOXY 1,2,3,4 TETRAHYDRONAPHTHALEN 1 YL)PROPYL DERIVATIVE; N (6 METHOXYNAPHTHALEN 1 YL)PROPYL DERIVATIVE; NAPHTHALENE DERIVATIVE; PIPERIDINE DERIVATIVE; SIGMA 1 OPIATE RECEPTOR; SIGMA 2 OPIATE RECEPTOR; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; GLIOMA CELL; ISOMER; LIGAND BINDING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT; RECEPTOR BLOCKING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; CELL PROLIFERATION; METHYLATION; NAPHTHALENES; PIPERIDINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, SIGMA; STEROID ISOMERASES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 29744457714     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050654o     Document Type: Article

References (49)

1. Su, T.-P. Sigma receptors in the central nervous system and the periphery. In The sigma receptors; Itzhak, Y., Ed.; Academic Press: London, 1994; pp 21-44.
2. Wolfe, S. A. Jr; De Souza, E. B. Role of sigma binding sites in the modulation of endocrine and immune functions. In The sigma receptors; Itzhak, Y., Ed.; Academic Press: London, 1994; pp 287-317.
3. Guitart, X.; Codony, X.; Monroy, X. Sigma receptors: Biology and therapeutic potential. Psychopharmacology 2004, 174, 301-319.
4. Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J. M.; Rothman, R. B., Su T.-P.; Tam, S. W.; Taylor, D. P. A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 1992, 13, 85-86.
5. Kekuda, R.; Prasad, P. D.; Fei, Y.-J.; Leibach, F. H.; Ganapathy, V. Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). Biochem. Biophys. Res. Commun. 1996, 229, 553-558.
6. Moebius, F. F.; Striessnig, J.; Glossmann, H. The mysteries of sigma receptors: New family members reveal a role in cholesterol synthesis. Trends Pharmacol. Sci. 1997, 18, 67-70.
7. Bowen, W. D. Sigma receptors: Recent advances and new clinical potentials. Pharm. Acta Helv. 2000, 74, 211-218.
8. Hayashi, T.; Su, T. P. Regulation ankyrin dynamics; roles of sigma-1 receptors. PNAS 2001, 98, 491-496.
9. Vilner, B. J.; John, C. S.; Bowen, W. D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 1995, 55, 408-413.
10. Caveliers, V.; Everaert, H.; Lahoutte, T.; Dierickx, L. O.; John, C. S.; Bossuyt, A. Labelled sigma receptor ligands: Can their role in neurology and oncology be extended? Eur. J. Nucl. Med. 2001, 28, 133-135.
11. 1 receptors cause selective release of the death program in tumor and self-reliant cells and inhibit tumor growth in vitro and in vivo. Cancer Res. 2004, 64, 4875-4886.
12. Crawford, K. W., Bowen, W. D. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 2002, 62, 313-322.
13. 1 receptors. Nucl. Med. Biol., 2000, 27, 255-261.
14. 18F] fluoroethyl SA4503 as a PET ligand for the sigma receptor. Synapse 2002, 43, 259-267.
15. Kassoiu, M.; Dannals, R. F.; Liu, X.; Wong, D. F.; Ravert, H. T.; Scheffel, U. A. Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors. Bioorg. Med. Chem. 2005, 13, 3623-3626.
16. 99mTc]Oxotecnetium(V) complexes of amine-amide-dithiol chelates with dialkylaminoalkyl substituents as potential diagnostic probes for malignant melanoma. J. Med. Chem. 2001, 44, 3132-3140.
17. Hayashi, T.; Su, T. P. σ-1 Receptor ligands: Potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004,18(5), 269-284.
18. Su, T. P.; Hayashi, T. Understanding the molecular mechanism of sigma-1 receptors: Towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. Curr. Med. Chem. 2003, 10, 2073-2080.
19. 1 receptor agonists. Drug News Perspect. 2002,15, 617-625.
20. SA-4503 (AGY-94806). Drugs Future 2004, 29, 970.
21. 1 receptor agonist PRE-084 against the spatial learning deficit in aged rats. Eur. J. Pharmacol. 2001, 431, 223-227.
22. 1 receptor ligand and putative atypical anthipsychotic E-5842 on BDNF mRNA expression in the rat brain. Neuroreport 2002, 13, 2345-2348.
23. Nakazato, A.; Otha, K.; Sekiguchi, Y.; Okuyama, S.; Chaki, S.; Kawashima, Y.; Hatayama, K. Design, synthesis, structure-activity relationships, and biological characterization of novel arylalkoxyphenylalkylamine σ ligands as potential antipsychotic drugs. J. Med. Chem. 1999, 42, 1076-1087.
24. Maeda, D. Y.; Williams, W.; Bowen, W. D.; Coop, A. A sigma-1 receptor selective analogue of BD 1008. A potential substitute for (+)-opioids in sigma receptor binding assays. Bioorg. Med. Chem. Lett. 2000, 10, 17-18.
25. Maier, C. A.; Wunsch, B. Novel spiropiperidines as higly potent and subtype selective σ-receptor ligands. part 1. J. Med. Chem. 2002, 45, 438-448.
26. 1 receptor binding. J. Med. Chem. 1994, 37, 1214-1219.
27. Ablordeppey, S. Y.; Fischer, J. B.; Law, H.; Glennon, R. A. Probing the proposed phenyl-A region of the sigma-1 receptor. Bioorg. Med. Chem. 2002, 10, 2759-2765.
28. Ablordeppey, S. Y.; Fischer, J. B.; Glennon, R. A. Is a nitrogen atom an important pharmacophoric element in sigma ligand binding? Bioorg. Med. Chem. 2000, 8, 2105-2111.
29. Yamamoto, H.; Miura, R.; Yamamoto, T.; Shinohara, K.; Watanabe, M.; Okuyama, S.; Nakazato, A.; Nukada, T. Amino acid residues in the transmembrane domain of the type 1 sigma receptor critical for ligand binding. FEBS Lett. 1999, 445, 19-22.
30. Gund, T. M.; Floyd, J.; Jung, D. Molecular modeling of σ1 receptor ligands: A model of binding conformational and electrostatic considerations. J. Mol. Graph. Model. 2004, 22, 221-230.
31. 2 ligands. J. Med. Chem. 1998, 41, 3940-3947.
32. 2 activity. J. Med. Chem. 2004, 47, 2308-2317.
33. 1 and EBP sites. Bioorg. Med. Chem. 2001, 9, 1325-1335.
34. 7 isomerase sites. J. Med. Chem. 2003, 46, 2117-2124.
35. Maeda, D. Y.; Williams, W.; Kim, W. E.; Tatcher, L. N.; Bowen, W. D.; Coop, A. N-Arylpiperidines as high affinity sigma-1 and sigma-2 receptor ligands: Phenylpropylamines as potential leads for selective sigma-2 agents. Bioorg. Med. Chem. 2002, 12, 497-500.
36. 1 antagonists in tumour cell lines. Naunyn-Schmiedeberg's Arch. Pharmacol. 2004, 370, 106-113.
37. 1A receptor. Affinity studies of 1-phenyl-4-[ω-(α- or β-tetralinyl)alkyl]piperazines. 4. J. Med. Chem. 1996, 39, 4928-4934.
38. Teran, C.; Miranda, R.; Santana, L.; Teijeira, M.; Uriarte, E. Synthesis of linear and angular benzofurocoumarins. Synthesis 1997, 1384-1386.
39. Castro, P. J. L.; Carling W. R.; Chambers, M. S.; Fletcher, S. R.; Hobbs, S. C.; Matassa, V. G.; Moore, K. W.; Showell, G. A.; Russel, M. G. N. Benzodiazepine derivatives. Merck Sharp and Dohme Ltd. PCT Int. Appl. WO 94 03,437, 1994; GB Appl. 92/16, 123, 1992; Chem. Abstr. 1994, 121, 35639j.
40. Hayashi, T.; Sawamura, M.; Ito, Y. Asymmetric synthesis catalyzed by chiral ferrocenylphosphine-transition metal complexes. 10 Gold(I)-catalyzed asymmetric aldol reaction of isocyanoacetate. Tetrahedron 1992, 48, 1999-2012.
41. Marawaha, J.; Palmer, M.; Hoffer, B.; Freedman, R.; Rice, K. C.; Paul, S.; Skolnick, P. Differential electrophysiological and behavioural responses to optically active derivatives of phencyclidine. Naunyn-Schmiedeberg's Arch. Pharmacol. 1981, 375, 203-209.
42. Adamo, M. F. A.; Aggarwal, V. K.; Sage, M. A. An improved resolution of 2-methylpiperidine and its use in the synthesis of homochiral trans-2,6-dialkyl piperidines. Synth. Commun. 1999, 1747-1756.
43. ClogP version 4.0 for Windows, BioByte Corp., Claremont, CA.
44. Prism ver 3.0 (version for Windows), GraphPad Software Inc., San Diego, CA.
45. Ablordeppey, S. Y.; Fischer, J. B.; Burke Howie, K. J.; Glennon, R. A. Design synthesis and binding of sigma receptor ligands derived from butaclamol. Med. Chem. Res. 1992, 2, 368-375.
46. 2 Receptors regulate changes in sphingolipid levels in breast tumor cells. Eur. J. Pharmacol. 2002, 443, 207-209.
47. Matsumoto, R. R.; Bowen, W. D.; Tom, M. A.; Nhi Vo, V.; Truong, D. D.; de Costa, B. R. Characterization of two novel σ receptor ligands: Antidystonic effects in rats suggest σ receptor antagonism. Eur. J. Pharmacol. 1995, 280, 301-310.
48. 2+ antagonist binding protein from guinea pig liver endoplasmic reticulum. J. Biol. Chem. 1994, 269, 29314-29320.
49. Mossman, T. Rapid colorimetric assay for cellular growth and survival. J. Immunol. Methods 1983, 65, 55-63.